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Purpose or Objective: Radio(chemo)therapy is a crucial 
treatment modality for head and neck squamous cell 
carcinoma (HNSCC). Radiotherapy resistance is a major 
reason for therapy failure and, therefore, predictive 
biomarkers for therapy response are urgently needed. DNA 
gains on chromosome 16q23-24 have been shown to be 
associated with genomic amplification of the FancA gene and 
to correlate with reduced progression-free survival of HNSCC 
patients after radiotherapy. This study aimed to analyze the 
effects of the potential predictive marker FancA on radiation 
sensitivity in vitro, to characterize the underlying molecular 
mechanisms, and to evaluate the clinical relevance in HNSCC. 
 
Material and Methods: We generated FancA overexpressing 
human oral keratinocytes (OKF6/FancA) and analyzed several 
endpoints upon irradiation. To identify signaling pathways 
involved in FancA-mediated resistance, global transcriptome 
analyses were performed after irradiation with 4 Gy or sham-
irradiation followed by pathway enrichment analysis and 
reconstruction of function interaction networks. The clinical 
relevance of the cytogenetic marker 16q23-24, the FancA 
gene and our in vitro results was analyzed in data of 113 
radiotherapy-treated patients from The Cancer Genome Atlas 
(TCGA) HNSCC cohort (Nature, 2015). 
 
Results: Overexpression of FancA resulted in enhanced 
survival after in vitro irradiation. Moreover, FancA 
overexpressing cells demonstrated accelerated DNA damage 
repair mechanisms paralleled by increased repair fidelity: 
enhanced p53 and p21 response, accelerated kinetics in the 
disappearance of γ-H2AX DNA damage repair foci, faster 
pATM translocation, reduced accumulation of chromosomal 
translocations, but no increase in FancD2 mono-
ubiquitinylation. Global mRNA expression analyses identified 
interferon signaling as a major candidate pathway, which was 
affected by FancA overexpression. Functional interaction 
networks of genes deregulated upon irradiation pointed to 
pathways exclusively involved in FancA-mediated 
radioresistance including the senescence-associated secretory 
phenotype (SASP). Increased levels of basal and irradiation-
induced cellular senescence accompanied by enforced SASP 
formation further support their potential involvement in 
FancA-mediated radiation resistance. The clinical relevance 
of our findings was validated in the data of 113 radiotherapy-
treated patients of the TCGA HNSCC cohort demonstrating 
the association of chromosomal gains on 16q24.3 with 
increased FancA mRNA expression levels and impaired overall 
survival. Furthermore, the translation of our in vitro model 
derived results into the HNSCC patient specimens revealed 
similar gene expression changes linked to FancA 
overexpression. 
 
Conclusion: Our data suggest an important role for FancA in 
cellular mechanisms of radioresistance in HNSCC. 
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Purpose or Objective: The addition of hypoxia modifiers 
carbogen and nicotinamide (CON) to radiotherapy (RT) 
improved overall survival in bladder cancer patients enrolled 
in the BCON phase III clinical trial. We investigated whether 
the expression of miR-210 in the BCON patient samples 
reflects hypoxia and predicts benefit from hypoxia-
modification. 
 
Material and Methods: The retrospective study involved 183 
T1-T4b patients: 86 received RT+CON and 97 received RT 
alone. Formalin-fixed samples taken prior to radiotherapy 
were available and RNA extracted. Customised TaqMan plates 
were used to assess miR-210 expression using quantitative 
real-time PCR. Patients were classified as low miR-210 
(<median expression) or high miR-210 (≥ median). Data on 
other hypoxia biomarkers were available for comparison. 
 
Results: Patients with high miR-210 had a trend towards 
improved five-year OS with RT+CON (53.2%) compared with 
RT alone (37.8%; HR 1.68, 95% CI 0.95-2.95, P=0.08). No 
benefit was seen with low miR-210 (HR 1.02, 95% CI 0.58-
1.79, P=0.97). High expression of miR-210 was also associated 
with high HIF-1α protein (P=0.0008), CA9 protein (P=0.004), 
Glut-1 protein (P=0.02), expression of a 26-gene hypoxia 
signature (P=0.01), tumour necrosis (P=0.04) and concurrent 
pTis (P=0.03). 
 
Conclusion: High miR-210 expression may reflect tumour 
hypoxia and should be investigated further as a potential 
biomarker to identify bladder cancer patients who would 
benefit from hypoxia-modifying therapies. 
 
OC-0443  
Radiotherapy sensitivity in breast cancer is influenced by 
the DNA cytosine deaminase APOBEC3B 
P.N. Span
1Radboud University Medical Center, Department of 
Radiation Oncology, Nijmegen, The Netherlands 
1, A. Post1, J.W.M. Martens2, R.S. Harris3 
2Erasmus MC Cancer Institute, Department of Medical 
Oncology and Cancer Genomics Netherlands, Rotterdam, The 
Netherlands 
3University of Minnesota- Masonic Cancer Center, 
Department of Biochemistry- Molecular Biology- and 
Biophysics, Minneapolis, USA 
 
Purpose or Objective: The DNA cytosine deaminase APOBEC3 
proteins catalyze deamination of cytidines in single-stranded 
DNA, providing innate protection against retroviral 
replication. Recent studies have implicated APOBEC3B as a 
major source of mutation in breast cancer, suggesting a role 
for these enzymes in tumor initiation and/or progression. 
APOBEC3B expression levels were earlier found to correlate 
with poor outcomes for patients with estrogen receptor 
positive breast cancer, especially after Tamoxifen. Given its 
role in mutagenesis, we set out to assess whether APOBEC3B 
associates with radiosensitivity in breast cancer. 
 
Material and Methods: MCF7 breast cancer cells were 
cultured radioresistant by daily 2 Gy treatments or 
tamoxifen-resistant by continuous culturing in up to 10 uM 4-
OH-tamoxifen. The effect of irradiation on expression of 
APOBECs was assessed by RNAseq and qPCR in radiosensitive 
and radioresistant MCF7, and by qPCR in radioresistant MDA-
MB231 cells. Furthermore, we studied a retrospective cohort 
of 535 non-systemically treated breast cancer patients. The 
predictive power of APOBEC3B was assessed in patients that 
did or did not receive radiotherapy as part of their primary 
therapy. Next, we suppressed endogenous APOBEC3B in MCF-
